NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-CA-24-022 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-048 from the NIH Guide for Grants and Contracts
Notice NOT-HG-24-012 from the NIH Guide for Grants and Contracts
Notice NOT-MH-24-140 from the NIH Guide for Grants and Contracts
Notice NOT-AR-23-024 from the NIH Guide for Grants and Contracts
Notice NOT-EB-23-024 from the NIH Guide for Grants and Contracts
Notice NOT-DE-24-007 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-315 from the NIH Guide for Grants and Contracts. The overarching goal of this PAR is to support educational activities that complement and/or enhance the training of the clinical and research workforce, and bring awareness of Geroscience to members of the public, by supporting creative educational activities with a primary focus on the development and integration of basic, applied, translational, and clinical topics in Geroscience including: Curriculum or Methods Development, Courses for Skills Development, Research Experiences and Networking, Development of a Repository of Important Reviews and Opinion Pieces and Clinical Trials in Progress, Outreach and Creation of Lay Public Documents on Geroscience.
Notice NOT-HL-23-125 from the NIH Guide for Grants and Contracts
Notice NOT-DK-24-005 from the NIH Guide for Grants and Contracts
Notice NOT-DK-24-004 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-033 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-034 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-035 from the NIH Guide for Grants and Contracts
Notice NOT-OD-24-036 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DA-25-028 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to support the development of Clinical Outcome Assessments (COA) for Substance Use Disorders (SUD). The COA development plan is expected to progress into the FDA drug development tool qualification program. This notice of funding opportunity (NOFO) utilizes the UG3/UH3Phased Innovation Awards Cooperative Agreement grant mechanism that includes two phases. The applications responding to this NOFO should contain a COA development plan that will cover both UG3 and UH3 phases. In the first 2-year UG3 phasethe project must have a set of operational milestones to be completed by the end of this period. Once NIDA program has evaluated the progress of the UG3 phase and determined that the UG3 phase has been successfully completed, it transitions to the UH3 phase to be funded for three additional years.The goal of this NOFO is to expand the armamentarium of COA that are FDA qualified as drug development tool (DDT) in the context of use (COI) of a SUD. Achieving this goal will greatly facilitate the development of treatments for SUDs. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.
Funding Opportunity RFA-NR-24-003 from the NIH Guide for Grants and Contracts. Care delivery has traditionally approached a patients health as separate and distinct from their social context. This practice must be reimagined to make meaningful improvements in health, eliminate health disparities, and advance health equity. The purpose of the Bridge-to-Care Initiative is to advance research that leverages healthcare-community partnerships to address unmet health-related social needs among individuals and families and adverse social determinants of health (SDOH) within communities.
Notice NOT-CA-24-021 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-24-072 from the NIH Guide for Grants and Contracts. Through this notice of funding opportunity (NOFO), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this NOFO must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences.
Funding Opportunity PAR-24-085 from the NIH Guide for Grants and Contracts. The purpose of this reissuance is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of DCTD and OHAM. The proposed project must involve at least 1 clinical trial related to the scientific interests of one or more of the following research programs: Cancer Therapy Evaluation Program, Cancer Imaging Program, Cancer Diagnosis Program, Radiation Research Program, Complementary and Alternative Medicine Program and/or the HIV and AIDS Malignancies Research Programs. Applicants may propose to conduct an early phase trial by itself, or in combination with another research aim(s) as appropriate.